Becton, Dickinson and Company has struggled over the past decade, with a 10-year CAGR of only 5.1%. Read what keeps me on the ...

Shares of Becton Dickinson & Co. BDX rose 1.22% to $202.32 Wednesday, on what proved to be an all-around favorable trading ...

The stock's rise snapped a four-day losing streak.

We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

Becton, Dickinson and Company (BD) has received the US Food and Drug Administration’s (FDA) 510(k) clearance for the Phasix ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.

4 analysts have expressed a variety of opinions on Becton Dickinson BDX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their ...

Choice Dekho proudly announces the launch of its live SAP IBP Demand Planning training sessions, conducted by seasoned ...

Valued at a market cap of $57.1 billion, Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory ...

Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the ...